Bortezomib-based consolidation or maintenance therapy for multiple myeloma: a meta-analysis.

Blood Cancer J · 2020 · PMC7060191 · PMID 32144237

Europe PMC DOI

hedged sentences

0.0520

closest p · 1.0× alpha

0.0520

boldest claim

The sentences

a clear trendP = 0.052so close (0.05 < p ≤ 0.1)

To assess the role of bortezomib-based maintenance therapy specifically in patients after ASCT, we excluded the trial involving transplant-ineligible patients 24 and performed the meta-analysis again, which showed improved OS (HR = 0.72, 95% CI 0.54–0.96, P = 0.025) and a clear trend toward improved PFS (HR = 0.84, 95% CI 0.699–1.001, P = 0.052).

also in 19,460 other papers

did not reach statistical significanceno p-value reported

However, these findings did not reach statistical significance (Table 2 ).

also in 111,027 other papers

showed a trendno p-value reported

Our meta-analysis showed a trend of increased risk of grade ≥ 3 neurologic adverse events with bortezomib-based consolidation/maintenance.

also in 53,322 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.